Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using a Hydra Pen to inject topical finasteride and Minoxidil for hair loss treatment. A user reports no side effects after one week of use and plans to share results in two months.

The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.

The conversation discusses purchasing Avodart (dutasteride) at a low price, with the OP using 1mg daily for hair loss. Users inquire about the source, and OP confirms buying from Oxford Pharmacy in the UK.

A hair loss regimen that includes oral dutasteride and topical minoxidil, as well as occasional dermapen treatments; the user inquires about when they noticed most regrowth.

A user shared their hair loss journey, starting with minoxidil and finasteride, and later switching to dutasteride, but still experiencing hair loss. Other users discussed their experiences with dutasteride, noting side effects like shedding and reduced libido, but some reported maintaining their hair over time.

Hair loss treatments, such as Dutasteride, Minoxidil, and Finasteride. Advice is given to give the medications time to work and to consider a Hair Transplant in order to fill any gaps caused by continuing hair loss.

A 38-year-old user shared progress pictures after 3.5 months of using oral dutasteride, oral minoxidil, dermastamping, and Nizoral shampoo, reporting significant hair regrowth. The user is optimistic about further improvement, while others discuss the effectiveness and side effects of these treatments.

The user has been using dutasteride for 8 months, oral minoxidil for 3 years, and topical minoxidil on temples, with recent microneedling. They experienced thinning after switching from finasteride to dutasteride and are hoping for improvement by the 12-month mark.

A user shared their 8-month progress using dutasteride 0.5 mg and oral minoxidil 2.5 mg for hair loss, expressing disappointment with the results and considering increasing the dosage. Other users advised patience, suggesting that improvements can continue over time, and recommended consulting a dermatologist before making changes.

The user's experience with hair loss treatments such as finasteride, dutasteride, and minoxidil, and how they are affecting their density. Replies to the post suggest different hairstyles and hair transplant options, and provide encouragement for the original poster's situation.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

A 23-year-old has been using 0.5mg Dutasteride and 5mg oral Minoxidil daily for two years, but their hair has thinned considerably. Suggestions include increasing the Dutasteride dose, adding Finasteride, or considering a hair transplant.

Hair loss treatments like minoxidil, finasteride, and dutasteride, with mixed results and suggestions for combining treatments or considering hair transplants. Some users experience no improvement or side effects.

A user's experience with hair loss treatments, specifically finasteride/dutasteride, and the potential for nocebo effects to influence side-effects. They caution others against focusing too much on possible side-effects when using these drugs, as they are generally safe and effective.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

A 54-year-old user shares progress after 3 years on dutasteride, following 15 years on finasteride, using 0.5 mg/day dutasteride, topical minoxidil every other day, and a peptide serum on alternate days. They experienced a significant shed during the transition but are now maintaining hair, noticing some new growth along the hairline.

The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.

A user took finasteride for six months, then switched to dutasteride for a year, increasing the dosage over time, but hair shedding worsened. Replies suggest the issue is male pattern baldness and DHT-related.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

People discussing their experiences with hair loss treatments found that switching from finasteride (Fin) to dutasteride (Dut) often resulted in improved hair thickness and health, despite some experiencing side effects or shedding phases. Some users switched due to diminishing results with Fin, while others were curious about the potential for better outcomes with Dut.

The conversation humorously discusses hair loss treatments, including minoxidil and finasteride, with a satirical suggestion of using fence castration as a natural finasteride for male deer. Participants joke about the side effects and effectiveness of these treatments.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.